Astria Therapeutics Inc - Asset Resilience Ratio
Astria Therapeutics Inc (ATXS) has an Asset Resilience Ratio of 48.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ATXS liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Astria Therapeutics Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Astria Therapeutics Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Astria Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ATXS market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $131.44 Million | 48.35% |
| Total Liquid Assets | $131.44 Million | 48.35% |
Asset Resilience Insights
- Very High Liquidity: Astria Therapeutics Inc maintains exceptional liquid asset reserves at 48.35% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Astria Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Astria Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Astria Therapeutics Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Astria Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 78.37% | $268.31 Million | $342.36 Million | +50.49pp |
| 2023-12-31 | 27.88% | $71.00 Million | $254.67 Million | -61.40pp |
| 2022-12-31 | 89.28% | $205.91 Million | $230.63 Million | +58.70pp |
| 2021-12-31 | 30.58% | $39.00 Million | $127.51 Million | -11.56pp |
| 2020-12-31 | 42.14% | $20.00 Million | $47.46 Million | -20.91pp |
| 2019-12-31 | 63.06% | $26.34 Million | $41.78 Million | +6.18pp |
| 2018-12-31 | 56.87% | $22.28 Million | $39.17 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $17.90 Million | -- |
| 2016-12-31 | 37.13% | $14.93 Million | $40.21 Million | -- |
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more